Carolina González Riaño

Dr. Carolina González Riaño

CEU San Pablo University, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
CRCarolina González Riaño
Carolina González Riaño
AGAntonia García
Antonia García
CBCoral Barbas
Coral Barbas

11 March 2017 in Brain Structure and Function
Verified
Journal Article
Open access
PDF file
CRCarolina González Riaño
Carolina González Riaño
Silvia Tapia GonzálezSilvia Tapia González
Silvia Tapia González
AGAntonia García
Antonia García
AMAlberto Muñoz
Alberto Muñoz
JDJavier DeFelipe
Javier DeFelipe
CBCoral Barbas
Coral Barbas
Understanding the human brain is the ultimate goal in neuroscience, but this is extremely challenging in part due to the fact that brain tissue obtained from autopsy is practically the only source of normal brain tissue and also since changes at different levels of biological organization (genetic, molecular, biochemical, anatomical) occur after death due to multiple mechanisms. Here we used metabolomic and anatomical techniques to study the possible relationship between post-mortem time (PT)-induced changes that may occur at both the metabolomics and anatomical levels in the same brains. Our experiments have mainly focused on the hippocampus of the mouse. We found significant metabolomic changes at 2 h PT, whereas the integrity of neurons and glia, at the anatomical/ neurochemical level, was not significantly altered during the first 5 h PT for the majority of histological markers.

1 June 2022 in Analytica Chimica Acta
Verified
Journal Article
Closed access
Mª Fernanda Rey-Stolle ValcarceMª Fernanda Rey-Stolle Valcarce
Mª Fernanda Rey-Stolle Valcarce
DDDanuta Dudzik
Danuta Dudzik
CRCarolina González Riaño
Carolina González Riaño
MFMiguel Fernández-García
Miguel Fernández-García
VAVanesa Alonso-Herranz
Vanesa Alonso-Herranz
AGAntonia García
Antonia García

16 August 2021 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
CRCarolina González Riaño
Carolina González Riaño
JSJorge Saiz
Jorge Saiz
CBCoral Barbas
Coral Barbas
ABAlberto Bergareche
Alberto Bergareche
JHJosé Mª Huerta
José Mª Huerta
PAPilar Amiano
Pilar Amiano
The lack of knowledge about the onset and progression of Parkinson’s disease (PD) hampers its early diagnosis and treatment. Metabolomics might shed light on the PD imprint seeking a broader view of the biochemical remodeling induced by this disease in an early and pre-symptomatic stage and unveiling potential biomarkers. To achieve this goal, we took advantage of the great potential of the European Prospective Study on Nutrition and Cancer (EPIC) cohort to apply metabolomics searching for early diagnostic PD markers. This cohort consisted of healthy volunteers that were followed for around 15 years until June 2011 to ascertain incident PD. For this untargeted metabolomics-based study, baseline preclinical plasma samples of 39 randomly selected individuals that developed PD (Pre-PD group) and the corresponding control group were analyzed using a multiplatform approach. Data were statistically analyzed and exposed alterations in 33 metabolites levels, including significantly lower levels of free fatty acids (FFAs) in the preclinical samples from PD subjects. These results were then validated by adopting a targeted HPLC-QqQ-MS approach. After integrating all the metabolites affected, our finding revealed alterations in FFAs metabolism, mitochondrial dysfunction, oxidative stress, and gut–brain axis dysregulation long before the development of PD hallmarks. Although the biological purpose of these events is still unknown, the remodeled metabolic pathways highlighted in this work might be considered worthy prognostic biomarkers of early prodromal PD. The findings revealed by this work are of inestimable value since this is the first study conducted with samples collected many years before the disease development.

9 January 2019 in Journal of Proteome Research
Verified
Journal Article
Closed access
CRCarolina González Riaño
Carolina González Riaño
GEGonzalo León Espinosa
Gonzalo León Espinosa
MRMamen Regalado-Reyes
Mamen Regalado-Reyes
AGAntonia García
Antonia García
JDJavier DeFelipe
Javier DeFelipe
CBCoral Barbas
Coral Barbas

5 January 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
BRBelén Fernández Requena
Belén Fernández Requena
SNSajid Nadeem
Sajid Nadeem
VRVineel P. Reddy
Vineel P. Reddy
VNVanessa Naidoo
Vanessa Naidoo
JGJoel N Glasgow
Joel N Glasgow
CRCarolina González Riaño
Carolina González Riaño
Accurate lipid annotation is crucial for understanding the role of lipids in health and disease and identifying therapeutic targets. However, annotating the wide variety of lipid species in biological samples remains challenging in untargeted lipidomic studies. In this work, we present a lipid annotation workflow based on LC-MS and MS/MS strategies, the combination of four bioinformatic tools, and a decision tree to support the accurate annotation and semi-quantification of the lipid species present in lung tissue from control mice. The proposed workflow allowed us to generate a lipid lung-based ATLAS (LiLA), which was then employed to unveil the lipidomic signatures of the Mycobacterium tuberculosis infection at two different time points for a deeper understanding of the disease progression. This workflow, combined with manual inspection strategies of MS/MS data, can enhance the annotation process for lipidomic studies and guide the generation of sample-specific lipidome maps. LiLA serves as a freely available data resource that can be employed in future studies to address lipidomic alterations in mice lung tissue.